
Letrozole
Letrozole
- SKU
- 50268-476
- Mfr
- AvPAK
1 tablet in 1 blister pack, 50 blister pack in 1 box
$307.72
28 packs × $10.99 each
Minimum order: 28 packs. Each product is sold in quantities worth at least $300.00.
Prescription required. Upload your prescription at checkout or email it to us after ordering. We ship once a pharmacist has checked it. How it works
1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
- Strength
- Letrozole 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet
- Route
- Oral
Pharmacologic class
- Aromatase InhibitorEstablished class
- Aromatase InhibitorsMechanism
- Brand name
- Letrozole
- Generic name
- Letrozole
- Manufacturer
- AvPAK
- Product NDC (SKU)
- 50268-476
- Active ingredients
- Letrozole 2.5 mg/1
- Unit of measure
- Per 1 tablet
- Dosage form
- Tablet
- Route
- Oral
- DEA schedule
- Not controlled
- Product type
- HUMAN PRESCRIPTION DRUG
- Marketing category
- ANDA
- Application number
- ANDA200161
- Marketed since
- October 2, 2019
- Label revised
- January 20, 2026
| Package NDC | Description |
|---|---|
| 50268-476-15 | 50 BLISTER PACK in 1 BOX (50268-476-15) / 1 TABLET in 1 BLISTER PACK |
Reading this NDC
50268-476-15
- 01Labeler code
- AvPAK
- 02Product code
- Letrozole, tablet
- 03Package code
- 50 blister pack in 1 box (50268-476-15) / 1 tablet in 1 blister pack
The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents).
These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.
Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.
Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.
Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer
Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy
First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer
Adjuvant
Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
Extended Adjuvant
Treatment of Early Breast Cancer Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies
].
First and Second-Line
Treatment of Advanced Breast Cancer Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies
].
Read before you order

Women's health · 2 min read
The combined pill vs the progestogen-only pill
How combined and progestogen-only contraceptive pills differ, who each suits, the side effects and what to do about a missed pill.

Women's health · 2 min read
Menopause hormone therapy (HRT) explained
How HRT relieves hot flushes and other menopause symptoms, why a progestogen is needed, patches vs tablets and the risks in context.

Women's health · 1 min read
Clomiphene for fertility: how ovulation induction works
How clomiphene triggers ovulation, how a treatment cycle is timed and monitored, the chance of twins and the side effects.
More in Women's Health
View all
Brand · Tablet
Activella
Estradiol .5 mg/1, Norethindrone Acetate .1 mg/1
- SKU
- 60846-231
- Mfr
- Amneal Pharmaceuticals LLC
From $30.99Min. 10 packs

Brand · Tablet
Angeliq
Estradiol .5 mg/1, Drospirenone .25 mg/1
- SKU
- 50419-482
- Mfr
- Bayer HealthCare Pharmaceuticals Inc.
From $120.99Min. 3 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 0713-0885
- Mfr
- Cosette Pharmaceuticals, Inc.
From $224.99Min. 2 packs

Generic · Tablet
Clomid
Clomiphene Citrate 50 mg/1
- SKU
- 50090-6500
- Mfr
- A-S Medication Solutions
From $678.99